These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 19328563)

  • 1. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
    Mannucci E; Monami M; Di Bari M; Lamanna C; Gori F; Gensini GF; Marchionni N
    Int J Cardiol; 2010 Aug; 143(2):135-40. PubMed ID: 19328563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
    Nagajothi N; Adigopula S; Balamuthusamy S; Velazquez-Cecena JL; Raghunathan K; Khraisat A; Singh S; Molnar J; Khosla S; Benatar D
    Am J Ther; 2008; 15(6):506-11. PubMed ID: 19127132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rosiglitazone meta-analysis.
    McCullough PA; Lepor NE
    Rev Cardiovasc Med; 2007; 8(2):123-6. PubMed ID: 17603430
    [No Abstract]   [Full Text] [Related]  

  • 6. [Rosiglitazone--statistics for benefits and problems].
    Hjelmesaeth J; Røislien J
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2702-3. PubMed ID: 17952157
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular risk of rosiglitazone: another perspective.
    Waksman JC
    J Pharm Pharmacol; 2008 Dec; 60(12):1573-82. PubMed ID: 19000361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rough road for rosiglitazone.
    Goldfine AB
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):113-7. PubMed ID: 18316944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
    Singh S; Loke YK; Furberg CD
    JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
    Mannucci E; Monami M; Lamanna C; Gensini GF; Marchionni N
    Diabetes Obes Metab; 2008 Dec; 10(12):1221-38. PubMed ID: 18505403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?
    Schernthaner G; Chilton RJ
    Diabetes Obes Metab; 2010 Dec; 12(12):1023-35. PubMed ID: 20977573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rosigliazone meta-analysis: lessons for the future.
    Shuster JJ; Schatz DA
    Diabetes Care; 2008 Mar; 31(3):e10. PubMed ID: 18308673
    [No Abstract]   [Full Text] [Related]  

  • 13. Faster publication isn't always better.
    Fuster V; Farkouh ME
    Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):345. PubMed ID: 17589426
    [No Abstract]   [Full Text] [Related]  

  • 14. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
    Cobitz A; Zambanini A; Sowell M; Heise M; Louridas B; McMorn S; Semigran M; Koch G
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):769-81. PubMed ID: 18613278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
    Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone and myocardial infarction: cause for concern or misleading meta-analysis?
    Bilous RW
    Diabet Med; 2007 Sep; 24(9):931-3. PubMed ID: 17725705
    [No Abstract]   [Full Text] [Related]  

  • 17. Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death.
    Shuster JJ; Jones LS; Salmon DA
    Stat Med; 2007 Oct; 26(24):4375-85. PubMed ID: 17768699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone, marketing, and medical science.
    Moynihan R
    BMJ; 2010 Apr; 340():c1848. PubMed ID: 20375091
    [No Abstract]   [Full Text] [Related]  

  • 19. Rosiglitazone, myocardial ischemic risk, and recent regulatory actions.
    Bourg CA; Phillips BB
    Ann Pharmacother; 2012 Feb; 46(2):282-9. PubMed ID: 22298606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone.
    Hernandez AV; Walker E; Ioannidis JP; Kattan MW
    Am Heart J; 2008 Jul; 156(1):23-30. PubMed ID: 18585493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.